Corrigendum

Poster Viewing Sessions PB01-B01 to PB03-V09. J Cereb Blood Flow Metab 2019; 39 (1S): 167–523. In the first publication of this section of the abstract book, the following abstracts were missing. Also, this section is to be titled, ‘BRAIN Poster Sessions PB01-B01 to PB03-V09’.

PB01-U06

Capillary endothelial phosphatidylinositol 4,5-bisphosphate (PIP2) rescues the disruption of Kir2-mediated retrograde hyperpolarization during neurovascular coupling in CADASIL mouse model

F. Dabertrand^1,2,3 O.F. Harraz³ M. Koide³ T.A. Longden³ A. Joutel⁴ M.T. Nelson^3,5

¹Department of Anesthesiology, University of Colorado, Anschutz Medical Campus, CO, USA

²Department of Pharmacology, University of Colorado, Anschutz Medical Campus, CO, USA

³Department of Pharmacology, University of Vermont, College of Medicine, VT, USA

⁴Institute of Psychiatry and Neuroscience of Paris, INSERM U894, Université Paris Descartes, France

⁵Institute of Cardiovascular Sciences, University of Manchester, Manchester, M13 9NT, UK

Small vessel disease (SVD) of the brain refers to a group of pathological processes leading to cerebral lesions, vascular cognitive decline and stroke. The understanding of the SVD pathogenesis is limited and there is no specific treatment. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a hereditary form of SVD caused by dominant mutations in the NOTCH3 gene, expressed predominantly by smooth muscles and pericytes. Recent studies in patients and in a genetic mouse model have revealed an impairment of neurovascular coupling (NVC), which matches local cerebral blood flow to increased neuronal activity, at an early stage of the disease. Yet the mechanism of disruption is not known. During normal NVC, increases in extracellular K⁺ concentration, resulting from neuronal activity, activate inward-rectifier K⁺ (Kir2.1) channels on capillary endothelial cell (cEC) to produce a rapidly propagating retrograde hyperpolarization that causes upstream arteriolar dilation, increasing blood flow into the capillary bed. Using conventional whole cell patch clamp, we measured a 50% reduction in Kir2.1 current in cECs from CADASIL mice. Along the same line, stimulation of capillaries with 10 mM K⁺ failed to trigger upstream arteriolar dilation in an innovative ex vivo capillary-parenchymal arteriole preparation and did not increase RBC flux measured in vivo using two-photon laser-scanning microscopy. We previously identified phosphatidylinositol 4,5-bisphosphate (PIP2) as a necessary requirement for capillary-to-arteriole Kir2.1-mediated electrical signaling, so we hypothesized that lower PIP2 level in cECs was responsible for crippled NVC in CADASIL mouse. We found that addition of diC16-PIP2, a soluble form of the phospholipid, to the bath solution in patch clamp experiments restores Kir2.1 current density to control levels. Confocal microscopy with a soluble form of PIP2 labelled with a BODIPY fluorophore confirmed that exogenous PIP2 was taken up by the capillary endothelial cells in the ex vivo capillary-parenchymal arteriole experiment, and we assessed the mobility of PIP2 in the plasma membrane of these cells by fluorescence recovery after photobleaching (FRAP). Finally, addition of soluble PIP2 restores electrical signaling in capillary-parenchymal arteriole preparation from CADASIL mouse as evidenced by the upstream arteriolar dilation in response to capillary stimulation with 10 mM K⁺. This dilation is inhibited by the specific Kir2 blocker Ba²⁺ (30 µM), and exogenous PIP2 had no effect on control animals and endothelial-specific Kir2.1-knockout mice. In conclusion, our study supports the concept that exogenous PIP2 restores Kir2.1-mediated currents and capillary-to-arteriole electrical signaling in CADASIL mouse model.

PB01-W05

Diffusion tensor imaging study of early gait training using Hybrid Assistive Limb in patients with acute stroke

D. Ando¹ C. Yokota^1,2 T. Sato¹ F. Yasuno³ A. Yamamoto⁴ M. Koga¹ M. Ihara⁵ T. Nakajima⁶ K. Minematsu¹ K. Koshino⁷

¹Dept. of Neuromedicine, National Cerebral and Cardiovascular Center, Japan

²Division of Stroke rehabilitation, Cerebral and Cardiovascular Center, Japan

³Department of Psychiatry, National Center for Geriatrics and Gerontology, Japan

⁴Department of Intellectual Assets Management, Research and Development Initiative Center, National Cerebral and Cardiovascular Center, Japan

⁵Department of Neurology, National Cerebral and Cardiovascular Center, Japan

⁶Niigata National Hospital, National Hospital Organization, Japan

⁷Department of Bio-Medical Imaging, National Cerebral and Cardiovascular Center Research Institute, Japan

Objectives: Early initiation of intension based errorless supervised motor learning following acute stroke could accelerate plastic reorganization from experimental studies. The aim of this study is to clarify the microstructural changes of white matter associated with gait training with Hybrid Assistive Limb (HAL FL-05) within 1 week of stroke onset.

Methods: Patients with acute stroke admitted within 48 hours of stroke onset from October 2016 to March 2018 were enrolled. The patients met the following criteria: first-ever stroke; required a walking aid; and ability to start gait training within 1 week of stroke onset. Patients were quasi-randomly assigned either to the conventional physical therapy without HAL (CPT group) or gait training using HAL (HAL group). Gait training was performed for 3 weeks in our hospital. In the HAL group, gait training using HAL was conducted 3 days a week and conventional physical therapy was performed another 2 or 3 days a week. All patients were discharged to a rehabilitation hospital to continue gait training without HAL until 3–5 months after stroke onset. Outcome measures, such as motor function and MRI, were collected at the 1^st (baseline) and 2^nd (at 3 to 5 months) assessments. Fractional anisotropy (FA) were calculated by fitting a diffusion tensor model. Voxel-based statistical analysis of FA images was carried out using diffusion metric voxel-wise analysis available in SPM 12. For close analysis of changes in FA between 2 assessments (ΔFA), we also performed a volume of interest (VOI) based analysis from significant clusters found in the voxel wise analysis.

Results: A total of 31 patients (17 from CPT group and 14 from HAL group, median age of 69 years) completed the study. No significant differences were demonstrated in patient characteristics including risk profiles, stroke severity, and a total amount of training time until the 2^nd assessment, and also no significant differences in total score of Functional Independence Measures as well as Functional Ambulation Categories at the 2^nd assessment. Voxel-based analyses of FA at the 2^nd assessment compared with those at the 1^st revealed significant decreases in the ipsilesional cerebral peduncle (CP) in the CPT group [(x, y, z,) = (-10, -16, -20) on a standard Montreal Neurological Institute brain space, cluster voxel size = 126, p = 0.003] and significant increases in the contralesional rostrum of corpus callosum (CC) in the HAL group [(x, y, z,) = (12, 22, -8), cluster voxel size = 46, p = 0.027] were observed, being consistent with mean ΔFA from the VOI analysis (CPT/HAL; CP, -0.064/-0.021, p = 0.004; CC, 0/0.031, P = 0.001).

Conclusions: Early initiation of gait training using HAL within 1 week of stroke onset may facilitate the recovery of the inter-hemispheric communication as well as the corticospinal tract in patients with acute stroke requiring.

PB02-C04

Correlation between cortical oxyhemoglobin and physiological changes after moderate-intensity exercise

A. Tsubaki¹ S. Morishita¹ Y. Tokunaga¹ K. Hotta¹ S. Kojima¹ W. Qin¹ H. Onishi¹

¹Institute for Human Movement and Medical Science, Niigata University of Health and Welfare

Objectives: A single bout of moderate-intensity cycling exercise improves brain function, including cognitive function. Increased cerebral blood flow or oxygenation during the exercise was suggested as causing these improvements. We found that measurement of cerebral oxyhemoglobin (O₂Hb) changes in the cerebral cortex using near-infrared spectroscopy shows that the O₂Hb levels increase during moderate-intensity exercise and persist at a higher level after the exercise in spite of the cessation of movement (Tsubaki et al. 2017; 2018). Some studies suggest that physiological parameters affect cerebral blood flow or oxygenation. The aim of this study was to determine the relationship between O₂Hb and physiological parameters related to ventilation after moderate-intensity exercise.

Methods: We recruited 12 healthy young volunteers (9 women; age, 21.2 ± 0.7 years) to participate in this study. After an incremental exercise test on a cycle ergometer to determine the VO₂ peak, the subjects performed another cycle ergometer exercise on a different day. After a 3-min rest period, the exercise was initiated at a workload corresponding to 50% VO₂ peak. The exercise continued for 20 min followed by a 15-min post-exercise rest. O₂Hb levels in the right (R-PFC) and left prefrontal cortices (L-PFC), right (R-PMA) and left premotor areas (L-PMA), supplemental motor area (SMA), and primary motor cortex (M1) were measured using a multi-channel near-infrared spectrometry system (OMM-3000, Shimadzu). Oxygen consumption (VO₂), end-tidal O₂ partial pressure (PETO₂), and CO₂ partial pressure (PETCO₂) were measured breath-by-breath during the experiments (AE-310S Minato Medical Science). The results were expressed as changes from the mean pre-exercise rest phase values and calculated every 60 s. To determine the relationship between O₂Hb and other ventilatory parameters, the Pearson correlation coefficient analysis was performed. Statistical significance was set at a p-value of <0.05.

Results: All the participants completed all the experiments. O₂Hb levels increased during the exercise and persisted 15 minutes from the time the participants stopped the exercise. A strong significant relationship between O₂Hb levels and PETO₂ was observed in all regions of interest (R-PFC, r = 0.924; L-PFC, r = 0.935; R-PMA, r = 0.902; L-PMA, r = 924; SMA, r = 839; M1, r = 0.827; all p < 0.01). However, O₂Hb levels and PETCO₂ had no significant correlation (r = 0.190–0.511, p > 0.05), except in the L-PFC (r = 0.529, p = 0.042). O₂Hb and VO₂ had moderate relationship in the R-PFC (r = 0.534, p = 0.040) and L-PFC (r = 0.549, p = 0.034) but had no significant correlation in the other regions (r = 0.201–0.333, p > 0.05).

Conclusions: O₂Hb level and PETO₂ showed strong relationships in the R-PFC, L-PFC, R-PMA, L-PMA, SMA, and M1 at the 15-min post-exercise rest after the 20-min moderate-intensity exercise.

References:

Tsubaki A, Takehara N, Sato D, et al. (2017) Cortical oxyhemoglobin elevation persists after moderate-intensity cycling exercise: a near-infrared spectroscopy study. Adv Exp Med Biol 977:261-268. doi:10.1007/978-3-319-55231-6_36

Tsubaki A, Morishita S, Tokunaga Y, et al. (2018). Changes in cerebral oxyhaemoglobin levels during and after a single 20-minute bout of moderate-intensity cycling. Adv Exp Med Biol 1072:127-131. doi: 10.1007/978-3-319-91287-5_20

In the first publication of the abstract book, authors were missing from the following abstracts. The full list of authors for these abstracts appears below.

Program Secretariat for Brain & Brain PET 2019 would like to apologize for this error.

BS11-6

Y. Takado¹, H. Takuwa¹, T. Urushihata¹, M. Takahashi¹, M. Ono¹, J. Maeda¹, M. Shimojo¹, N. Nitta², S. Shibata², I. Aoki², N. Sahara¹, T. Suhara¹ and M. Higuchi¹

¹Department of Functional Brain Imaging Research, Quantum and Radiological Science and Technology, Chiba, Japan

²Department of Molecular Imaging and Theranostics, Quantum and Radiological Science and Technology, Chiba, Japan

BPS05-5

A.P. Fan¹, K.T. Chen¹, C. Azevedo¹, J.B. Castillo¹, A. Nadiadwala², T.Toueg², S. Sha²,

G.A. Davidzon¹, F.T. Chin¹, G. Zaharchuk¹ and E.C. Mormino²

¹Department of Radiology, Stanford University, Stanford CA, USA

²Department of Neurology, Stanford University, Stanford CA, USA

BPS07-5

A.V. Venkataraman^1,2,8, A. Mansur^1,3,8, Y. Lewis^3,8, E. Kocagoncu⁵, A. Lingford-Hughes¹, M. Huiban^3,8, J. Passchier^3,8, J.B. Rowe^5,8, H. Tsukada^6,8, D. Brooks^7,8, R.N. Gunn^1,3,8, P.M. Matthews^1,2,8 and EA. Rabiner^1,4,8

¹Division of Brain Sciences, Imperial College London, UK

²UKDRI at Imperial College London

³Invicro LLC.

⁴King’s College London

⁵University of Cambridge

⁶Hamamatsu Photonics

⁷University of Newcastle

⁸MINDMAPS Consortium

PA00-A03

C. Cserép¹, B. Pósfai^1,10, B. Orsolits¹, G. Molnár², S. Heindl³, N. Lénárt¹, R. Fekete^1,10, Z. László⁴, Z. Lele⁴, A.D. Schwarcz¹, K. Ujvári¹, L. Csiba⁵, T. Hortobágyi⁶, Z. Maglóczki⁷, B. Martinecz¹, G. Szabó⁸, F. Erdélyi⁸, R. Szipőcs⁹, I. Katona⁴, A. Liesz³, G. Tamás² and Á. Dénes¹

¹Laboratory of Neuroimmunology, Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary

²MTA-SZTE Research Group for Cortical Microcircuits, Department of Physiology, Anatomy and Neuroscience, University of Szeged, Hungary

³Institute for Stroke and Dementia Research, Ludwig-Maximilians-University, Munich, Germany

⁴Laboratory of Molecular Neurobiology, Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest Hungary

⁵Department of Neurology, University of Debrecen, Debrecen, Hungary

⁶Division of Neuropathology, Institute of Pathology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

⁷Human Brain Research Laboratory, Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary

⁸Medical Gene Technology Unit, Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary

⁹Institute for Solid State Physics and Optics of Wigner RCP, Budapest, Hungary

¹⁰Szentágothai János Doctoral School of Neuroscience, Semmelweis University, Budapest, Hungary

PA00-A35

T.S. Ko¹, C.D. Mavroudis², R.W. Morgan³, A.M. Marquez³, W. Guo⁴, T.W. Boorady¹, M. Devarajan¹, Y. Lin³, W.P. Landis³, A.J. Lautz⁵, V.M. Nadkarni³, R.A. Berg³, R.M. Sutton³, A.G. Yodh⁶, D.J. Licht¹ and T.J. Kilbaugh³

¹Division of Neurology, Children’s Hospital of Philadelphia, USA

²Department of Cardiothoracic Surgery, University of Pennsylvania Health System

³Department of Anesthesiology and Critical Care, Children’s Hospital of Philadelphia

⁴Department of Epidemiology and Biostatistics, University of Pennsylvania

⁵Division of Critical Care, Cincinnati Children’s Hospital Medical Center

⁶Department of Physics and Astronomy, University of Pennsylvania

PB01-D07

M. Giovannella¹, B. Andresen², J.B. Andersen³, S. El-Mahdaoui², D. Contini⁴, L. Spinelli⁵, A. Torricelli^4,5, G. Greisen², T. Durduran^1,6, U.M. Weigel⁷ and I. Law³

¹ICFO-Institut de Ciències Fotòniques, The Barcelona Institute of Science and Technology, Spain

²Department of Neonatology, Copenhagen University Hospital - Rigshospitalet, Denmark

³Department of Clinical Physiology, Nuclear Medicine & PET, Copenhagen University Hospital -Rigshospitalet, Denmark

⁴Politecnico di Milano-Dipartimento di Fisica, Italy

⁵Istituto di Fotonica e Nanotecnologie, Consiglio Nazionale delle Ricerche, Italy

⁶Institució Catalana de Recerca i Estudis Avançats (ICREA), Spain

⁷HemoPhotonics S.L., Spain

PB01-K10

P.R. Jackson¹, M. Kim², A. Hawkins-Daarud¹, K.W. Singleton¹, A.S. Mohammad², T.C. Burns³, I.F. Parney³, L.S. Hu⁴, T.J. Kaufmann⁵, W.F. Elmquist², J.N. Sarkaria⁶ and K.R. Swanson¹

¹Precision Neurotherapeutics Innovation Program, Department of Neurological Surgery, Mayo Clinic, Phoenix, AZ, USA

²Brain Barriers Research Center, Department of Pharmaceutics, University of Minnesota, Minneapolis, MN, USA

³Department of Neurological Surgery, Mayo Clinic, Rochester, MN, USA

⁴Department of Radiology, Mayo Clinic, Phoenix, AZ, USA

⁵Department of Radiology, Mayo Clinic, Rochester, MN, USA

⁶Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA

PB01-V12

M.D. Schirmer^1,2,3, K.L. Donahue¹, M.J. Nardin¹, A.V. Dalca^2,4, AK. Giese¹, M.R. Etherton¹,

S.J.T. Mocking⁴, E.C. McIntosh⁴, J.W. Cole⁵, L. Holmegaard⁶, K. Jood⁶, J. Jimenez-Conde⁷,

S.J. Kittner⁵, R. Lemmens^8,9, J.F. Meschia¹⁰, J. Rosand^{1,4, 11}, J. Roquer⁷, T. Rundek¹²,

R.L. Sacco¹², R. Schmidt¹³, P. Sharma¹⁴, A. Slowik¹⁵, T.M. Stanne⁶, A. Vagal¹⁶, J. Wasselius¹⁷, D. Woo¹⁸, S. Bevan¹⁹, L. Heitsch²⁰, CL. Phuah²¹, D. Strbian²², T. Tatlisumak²³, C.R. Levi²⁴,

J. Attia²⁵, P.F. McArdle²⁶, B.B. Worrall²⁷, O. Wu⁴, C. Jern⁶, A. Lindgren²⁸, J. Maguire²⁹,

V. Thijs³⁰ and N.S. Rost¹

¹Stroke Division & Massachusetts General Hospital, J. Philip Kistler Stroke Research Center, Harvard Medical School, Boston, USA

²Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, Boston, USA

³Department of Population Health Sciences, German Centre for Neurodegenerative Diseases (DZNE), Germany

⁴Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, USA

⁵Department of Neurology, University of Maryland School of Medicine and Veterans Affairs Maryland Health Care System, Baltimore, MD, USA

⁶Institute of Biomedicine, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

⁷Department of Neurology, Neurovascular Research Group (NEUVAS), IMIM-Hospital del Mar (Institut Hospital del Mar d’Investigacions Mediques), Universitat Autonoma de Barcelona, Barcelona, Spain

⁸KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), Leuven, Belgium

⁹VIB, Vesalius Research Center, Laboratory of Neurobiology, University Hospitals Leuven, Department of Neurology, Leuven, Belgium

¹⁰Department of Neurology, Mayo Clinic, Jacksonville, FL, USA

¹¹Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA

¹²Department of Neurology and Evelyn F. McKnight Brain Institute, Miller School of Medicine, University of Miami, Miami, FL, USA

¹³Department of Neurology, Clinical Division of Neurogeriatrics, Medical University Graz, Graz, Austria

¹⁴Institute of Cardiovascular Research, Royal Holloway University of London (ICR2UL), Egham, UK St Peter’s and Ashford Hospitals, UK

¹⁵Department of Neurology, Jagiellonian University Medical College, Krakow, Poland

¹⁶Department of Radiology, University of Cincinnati College of Medicine, Cincinnati, OH, USA

¹⁷Department of Clinical Sciences Lund, Radiology, Lund University, Lund, Sweden; Department of Radiology, Neuroradiology, Skane University Hospital, Malmo, Sweden

¹⁸Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA

¹⁹School of Life Science, University of Lincoln, Lincoln, UK

²⁰Division of Emergency Medicine, Washington University School of Medicine, St Louis, MO, USA

²¹Department of Neurology, Washington University School of Medicine & Barnes-Jewish Hospital, St Louis, MO, USA

²²Division of Neurocritical Care & Emergency Neurology, Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland

²³Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden

²⁴School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia; Department of Neurology, John Hunter Hospital, Newcastle, NSW, Australia

²⁵Hunter Medical Research Institute, Newcastle, New South Wales, Australia; School of Medicine and Public Health, University of Newcastle, NSW, Australia

²⁶Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA

²⁷Departments of Neurology and Public Health Sciences, University of Virginia, Charlottesville, VA, USA

²⁸Department of Neurology and Rehabilitation Medicine, Skåne University Hospital, Lund, Sweden; Department of Clinical Sciences Lund, Neurology, Lund University, Lund, Sweden

²⁹University of Technology Sydney, Sydney, Australia

³⁰Stroke Division, Florey Institute of Neuroscience and Mental Health, Heidelberg, Australia; Department of Neurology, Austin Health, Heidelberg, Australia

PB02-D06

I. Şencan¹, K. Kılıç⁵, B. Li¹, B. Fu¹, J.E. Porter¹, T. Esipova², M. Desjardins³, M.A. Yaseen¹, D.A. Boas^1,5, S.A. Vinogradov², A. Devor^1,3,4 and S. Sakadžić¹

¹Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA

²Departments of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA 19104, USA

³Department of Neurosciences, University of California San Diego, La Jolla, CA 09293, USA

⁴Department of Radiology, University of California San Diego, La Jolla, CA 09293, USA

⁵Departments of Biomedical and Electrical and Computer Engineering, Boston University, Boston MA 02215, USA

PB03-G18

C. Gregori-Pla¹, R.C. Mesquita², C.G. Favilla³, D.R. Busch⁴, I. Blanco¹, L. Kobayashi Frisk¹, P. Camps-Renom⁵, M.T. Mullen³, J. Martí-Fàbregas⁵, L. Prats-Sánchez⁵, A. Martínez-Domeño⁵, R. Delgado-Mederos⁵, J.A. Detre³, A.G. Yodh⁶ and T. Durduran^1,7

¹ICFO-Institut de Ciències Fotòniques, The Barcelona Institute of Science and Technology, Barcelona, Spain

²Institute of Physics, University of Campinas, Campinas, Brazil

³Department of Neurology, University of Pennsylvania, Philadelphia, USA

⁴Anesthesiology and Pain Management, Neurology and Neurotherapeutics, University of Texas Southwestern, USA

⁵Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

⁶Department of Physics and Astronomy, University of Pennsylvania,Philadelphia, USA

⁷Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

PB03-L02

N. Kishida^1,2, T. Maki¹, Y. Takagi^2,3, K. Yasuda¹, H. Kinoshita¹, T. Ayaki¹, T. Noro¹, Y. Kinoshita⁴, Y. Ono⁴, H. Kataoka², K. Yoshida², E. Lo⁵, K. Arai⁵, S. Miyamoto², R. Takahashi¹

¹Department of Neurology, Graduate School of Medicine, Kyoto University, Japan

²Department of Neurosurgery, Graduate School of Medicine, Kyoto University

³Department of Neurosurgery, Graduate School of Medicine, Tokushima University

⁴Department of Developmental Neurobiology, KAN Research Institute, Inc.

⁵Departments of Radiology and Neurology, Massachusetts General Hospital and Harvard Medical School

PB03-Q04

T. Dragojevic¹, E.E. Vidal-Rosas¹, E. Masvidal-Codina², X. Illa^2,3, M. Dasilva⁴, A.B. Calia⁵, E. Prats-Alfonso^2,3, J. Martinez-Aguilar^2,3, J.M. De la Cruz⁴, R. Garcia-Cortadella⁵, P. Godignon², G. Rius², A. Camassa⁴, E. Del Corro^5, J. Bousquet⁵, C. Hebert⁵, T. Durduran^1,6, R. Villa^2,3, M.V. Sanchez-Vives^4,6, J.A. Garrido^5,6 and A. Guimera-Brunet^2,3

¹ICFO-Institut de Ciències Fotòniques, The Barcelona Institute of Science and Technology, Spain

²Instituto de Microelectronica de Barcelona, IMB-CNM (CSIC), Esfera UAB, Bellaterra, Spain

³Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.

⁴Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

⁵Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and The Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, Barcelona, Spain

⁶Institucio Catalana de Recerca i Estudis Avancats (ICREA), 08015 Barcelona, Spain

PB03-Q16

D. Milej^1,2, L. He³, A. Abdalmalak^1,2, W.B. Baker⁴, U.C. Anazodo^1,2, S. Dolui⁵, V.C. Kavuri³, M. Diop^1,2, W. Pavlosky², R. Balu⁵, J.A. Detre⁵, O. Amendolia⁶, F. Quattrone⁶, W.A. Kofke^4,6, A.G. Yodh³ and K. St Lawrence^1,2

¹Department of Medical Biophysics, Western University, London, Ontario, Canada

²Imaging Division, Lawson Health Research Institute, London, Ontario, Canada

³Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, USA

⁴Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, USA

⁵Department of Neurology, University of Pennsylvania, Philadelphia, USA

⁶Department of Neurosurgery, University of Pennsylvania, Philadelphia USA

PP01-M01

Y. Nagai¹, N. Miyakawa¹, H. Takuwa¹, Y. Hori¹, K. Oyama¹, B. Ji¹, M. Takahashi¹, XP. Haung², S.T. Slocum², Y. Xiong³, T. Hirabayashi¹, A. Fujimoto¹, K. Mimura¹, J.G. English², J. Liu³, K. Inoue⁴, K. Kumata⁵, C. Seki¹, M. Ono¹, M. Shimojo¹, MR. Zhang⁵, Y. Tomita⁶, T. Suhara¹, M. Takada⁴, M. Higuchi¹, J. Jin³, B.L. Roth² and T. Minamimoto¹

¹Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Japan

²Department Pharmacology, University of North Carolina at Chapel Hill School of Medicine, USA

³Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, USA

⁴Systems Neurosci. Section, Primate Res. Institute, Kyoto University, Japan

⁵Department of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Japan

⁶Department of Neurology, Keio University School of Medicine, Japan

PP01-N04

M. Vicente-Rodriguez^1,4, N. Singh¹, D. Cash^1,4, M. Veronese¹, C. Simmons^1,4, A.K. Haji-Dheere³, J. Bordoloi³, K. Sanders⁵, R. Awais⁵, E. Arstad⁵, NIMA Consortium, F. Turkheimer^1,4, C.A. Parker^2,4

¹Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, United Kingdom

²GlaxoSmithKline, Stevenage, London, United Kingdom

³PET Centre, St Thomas’ Hospital, London, United Kingdom

⁴The Wellcome Trust Consortium for the Neuroimmunology of Mood Disorders and Alzheimer’s Disease (NIMA)

⁵Institute of Nuclear Medicine and Department of Chemistry – Radiochemistry, University College London, United Kingdom

PP01-Q01

D. Erritzoe¹, B.R. Godlewska², G. Rizzo³, G.E. Searle³, Y. Lewis³, J. Passchier³, A. Ashok⁴,

O. Howes⁴, R.N. Gunn^1,3, D.J. Nutt¹, P. Cowen², G. Knudsen⁵ and E.A. Rabiner^3,4

¹Imperial College, London, UK

²University of Oxford, Oxford, UK

³Invicro, London, UK

⁴King’s College, London, UK

⁵Rigshospitalet and University of Copenhagen, Denmark

PP02-J02

C. Seki¹, K. Tagai^1,2, H. Shimada^1,3, K. Takahata¹, M. Kubota¹, Y. Takado¹, H. Shinotoh^1,4,

Y. Kimura¹, M. Ichise¹, M. Okada¹, T. Kikuchi¹, MR. Zhang¹ and M. Higuchi¹

¹National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Japan

²Department of Psychiatry, Jikei University School of Medicine

³Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan

⁴Neurology Clinic Chiba, Chiba-shi, Chiba, Japan

PP02-J03

T.G. Lohith¹, C. Sur¹, T. Taylor¹, N. Dupre¹, C. Furtek¹, Y. Wang¹, J. Kost¹, D. Scott²,

K. Adamczuk², E. Hostetler¹, J. Evelhoch¹, T. Voss¹ and M. Egan¹

¹MRL, Merck & Co., Inc., Kenilworth, NJ, USA

²Bioclinica, Newark, CA, USA

PP02-J06

R. Radhakrishnan¹, P. Worhunsky¹, MQ. Zheng², S. Najafzadeh², JD. Gallezot², B. Planeta², S. Henry², N. Nabulsi², M. Ranganathan¹, P.D. Skosnik¹, D. Cyril D’Souza¹, M.N. Potenza¹, R.E. Carson², Y. Huang² and D. Matuskey^1,2

¹Dept. of Psychiatry, Yale University School of Medicine, USA

²Dept. of Radiology and Biomedical Imaging, Yale University School of Medicine, USA

PP02-K03

J. Debatisse^1,2, O. Eker^3,4, O. Wateau⁵, N. Costes⁶, I. Mérida⁶, M. Verset⁵, A. Oudotte⁴,

AC. Lukaszewicz^4,7, JB. Langlois⁶, C. Léon¹, L. Augeul¹, C. Tourvielle⁶, S. Lancelot^4,6,

D. Le Bars^4,6, T. Troalen², H. Contamin⁵, TH. Cho^3,4 and E. Canet-Soulas¹

¹Univ Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Universit&eacute; Claude Bernard Lyon 1 - Lyon, France

²Siemens Healthcare SAS - Saint-Denis, France

³CREATIS, CNRS UMR 5220, INSERM U1206, Université Claude Bernard Lyon 1, INSA Lyon, Université Jean Monnet Saint-Etienne - Lyon, France

⁴Hospices Civils de Lyon - Lyon, France

⁵Cynbiose SAS - Marcy-L’Etoile, France

⁶CERMEP - Imagerie du vivant - Lyon, France

⁷Université Claude Bernard Lyon 1, Pathophysiology of Injury-Induced Immunosuppression, PI3, EA 7426 - Lyon, France

PP02-K07

Q. Qin^1,2, M. Zhang³, P. Huang⁴, W. Liu⁴, H. Meng³, B. Li³, B. Sun⁴, M. Lin⁵, M. Xu^1,2,

Z. Wang⁶, R.C. Stevens^1,2 and G.J. Thompson¹

¹iHuman Institute, ShanghaiTech University, China

²School of Life Science and Technology, ShanghaiTech University, China

³Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China

⁴Department of Functional Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China

⁵MR Collaboration, Siemens Healthcare Ltd., China

⁶Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, China

PP02-L01

M. Shimojo¹, M. Ono¹, H. Takuwa¹, K. Mimura¹, Y. Nagai¹, M. Fujinaga², T. Kikuchi²,

M. Okada², C. Seki¹, M. Tokunaga¹, J. Maeda¹, Y. Takado¹, M. Takahashi¹,

T. Minamihisamatsu¹, MR. Zhang², Y. Tomita³, N. Suzuki³, A. Maximov⁴, T. Suhara¹,

T. Minamimoto¹, N. Sahara¹ and M. Higuchi¹

¹Department of Functional Brain Imaging, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan

²Department of Radiopharmaceuticals Development, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan

³Department of Neurology, Keio University School of Medicine, Tokyo, Japan

⁴Department of Neuroscience, The Scripps Research Institute, La Jolla, USA

The figure below appeared alongside PB02-B17. It is for PB02-B14.

The following figure should have appeared next to PB02-B13